Form 4: BioCryst Pharmaceuticals Director Stock Transactions

Theresa Heggie, a Director at BioCryst Pharmaceuticals, reported transactions involving restricted stock units and stock options.

Summary

• Theresa Heggie, a Director at BioCryst Pharmaceuticals Inc. (BCRX), reported the acquisition of 15,294 shares of Common Stock on June 11, 2026, with no cost basis reported.
• Additionally, Heggie was granted 33,540 stock options with an exercise price of $8.50, vesting on June 11, 2027, and expiring on June 11, 2036.
• These transactions are part of an automatic non-employee director grant under the company's Director Compensation Policy.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents routine director compensation and equity grants rather than significant strategic or financial performance indicators.

Positives

• Director Heggie received a grant of restricted stock units and stock options, indicating continued equity incentive for non-employee directors.
• The stock options have a vesting period, aligning with long-term performance expectations.

Future Outlook

The filing does not contain forward-looking statements or guidance. It reports on past transactions.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into executive and director compensation and equity holdings within the pharmaceutical sector.

Stakeholder Impact

• Shareholders: Increased transparency into director compensation and equity ownership.

Key Dates

Keywords

Form 4, SEC Filing, BioCryst Pharmaceuticals, BCRX, Director, Stock Options, Restricted Stock Units, Equity Grant, Beneficial Ownership